Eprosartan Mesylate

依普沙坦甲磺酸盐

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NameEprosartan Mesylate
Drug Alias Nameeprosartanum依普罗沙坦甲磺酸依普罗沙坦Teveten SB甲磺酸依普沙坦 +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1997/12/22
Country/TerritoryUnited StatesRussian FederationGermany +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbott Healthcare Products Bv
Inactive CompaniesAbbott LaboratoriesAbbvie Inc
Active IndicationsHypertension
Inactive IndicationsEssential Hypertension

Other Information

ATC CodeC09CA02
Related LinksWikipediaDrugBankKEGG